Warner ready to return from retirement for India Test series
Warner, who accumulated 8,786 runs in 112 Tests, has recently played in limited-overs franchise competitions in Canada and the Cayman Islands.
Warner, who retired after the third Test against Pakistan in Sydney in January, has told Australian coach Andrew McDonald that he can step in if needed. (Photo: Getty Images)
By EasternEyeOct 23, 2024
DAVID Warner has informed Australian selectors that he is available to come out of retirement and play in the upcoming home Test series against India. The five-match Border-Gavaskar Trophy is set to begin in Perth on November 22.
The 37-year-old batsman said he is "dead serious" about his offer to return, particularly with Steve Smith aiming to move back to his preferred number four position, which leaves the selectors searching for an opening partner for Usman Khawaja.
Warner, who retired after the third Test against Pakistan in Sydney in January, has told Australian coach Andrew McDonald that he can step in if needed. However, McDonald appears less enthusiastic about the idea.
"I'm always available, just got to pick up the phone," Warner told News Corp on Tuesday. He suggested he could be a stronger option than players who have only just started their domestic Sheffield Shield season.
"I'm always dead serious. Let's be honest, the guys have played one red-ball game since their last Test matches in February, so I've almost had the same preparation. Honestly, if they really needed myself for this series, I’m more than happy to play the next Shield game and go out there and play."
Warner also noted McDonald’s response to his offer didn't indicate a recall was likely. "His answer back to me was, 'you retired'," Warner said. "I don't think he wants to give me the pleasure of him saying: Can you come back?"
Warner, who accumulated 8,786 runs in 112 Tests, has recently played in limited-overs franchise competitions in Canada and the Cayman Islands.
Meanwhile, Cameron Bancroft, Marcus Harris, and Matthew Renshaw are seen as contenders to open alongside Khawaja in the series against India.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.